QSV Biologics, Ltd. and Critical Biologics Corp. Sign 2nd Contract for cGMP Manufacture of Plasma Gelsolin
Plasma gelsolin (pGSN) is a naturally occurring, and highly evolutionary conserved, circulating plasma protein involved in the regulation and localization of inflammation. Severe depletion of plasma gelsolin has been found to correlate strongly with increased morbidity and mortality in a number of acute and chronic diseases. Experiments in animal models have shown that disease progression and adverse outcomes can be averted by a timely replenishment of plasma gelsolin using Solinex(TM). CBC is currently completing a Phase 2a placebo controlled safety and pharmacokinetic trial of Solinex(TM) in critical care patients identified as being at high-risk of developing sepsis using CBC's proprietary pGSN diagnostic assay, SolinDx(TM).
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.